Functional Dyspepsia

  • View
    1.347

  • Download
    9

Embed Size (px)

DESCRIPTION

Functional Dyspepsia

Text of Functional Dyspepsia

  • 1. CRISBERT I. CUALTEROS, M.D. Department of Family and Community Medicine Perpetual Succour Hospital

2.

  • Gerald Holtmann, M.D., Nicholas J. Talley, M.D., Ph.D., Tobias Liebregts, M.D.,
  • Birgit Adam, M.D., and Christopher Parow, M.D.
  • New England Journal of Medicine
  • February 23,2006; 354: page 832-840

3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. A positive response: improvement by at least one grade 15. 16. 17. 18. 19.

  • Improved symptom-severity scores on the LDQ from baseline in all four study groups.
  • Itopride was significantly superior to placebo during the testing of the global hypothesis
  • Placebo and itopride given at 50 mg TID was not significant (P 0.07)
  • Placebo & itopride at 100 mg TID &
  • at 200 mg TID were both significant (P 0.05)

20.

  • Testing of all planned hypotheses for response rates to patients global assessment of efficacy showed significant result
  • There was a significant association between the dose of itopride and the response rate
  • The global hypothesis on the response rates according to the severity of pain and fullness yielded a significant discrimination between itopride & placebo

21. Holtmann G et al. N Engl J Med 2006;354:832-840 Response Rates Based on Patients' Global Assessment of Efficacy 22.

  • NDI quality-of life scores were better among patients treated with active medication than placebo.
  • The NDI quality-of-life score improved by a mean of 13.2+/-19.4 with placebo and by 18.0+/-21.9 with itopride (P = 0.02).
  • However, differences between the various doses of itopride tested were not statistically significant.

23. Primary Outcome Variables among 523 Patients 24. 25. 26.

  • Thank you